You are here: Industry Insights > WACKER

News List

Genopis Renamed Wacker Biotech US contractpharma
March 22, 2021
Wacker Biotech US Inc. is the new name of Genopis Inc., the plasmid DNA manufacturer based in San Diego, CA, that Wacker acquired in February. The acquisition concerns a plasmid DNA (pDNA) CDMO site and its associated business.
Wacker Strengthens Biologics Business contractpharma
February 05, 2021
The Munich, Gemany-based chemical company Wacker is acquiring 100 percent of the shares in pharmaceutical contract manufacturer Genopis from South Korea-based firms Helixmith and Medivate Partners.
CureVac and Wacker Sign Contract for Manufacturing of Covid-19 Vaccine Candidate contractpharma
November 25, 2020
Manufacturing at Wacker’s biotech site in Amsterdam is scheduled to start in the first half of 2021.
Wacker Invests in Amsterdam Site contractpharma
July 30, 2020
Wacker, the Munich-based chemicals group, is investing in its production facilities for biologics, LMPs (live microbial products) and vaccines at its Amsterdam site.
Wacker Receives Excipient Certification contractpharma
March 25, 2020
EXCiPACT asbl has awarded Wacker Chemical Corporation’s site in Eddyville, IA, with an EXCiPACT GMP Certificate from SGS, one of EXCIPACT’s internationally recognized certification bodies.
WACKER Obtains FDA Approval to Manufacture the Drug Substance in Retavase, a Thrombolysis Medication biospace
January 10, 2018
Wacker Biotech GmbHwill produce the drug substance reteplase, the active ingredient in the drug Retavase®, which the pharmaceutical company Chiesi will market in the USA